Interventional Oncolytic Immunotherapy with LTX-315 for Residual Tumor after Incomplete Radiofrequency Ablation of Liver Cancer.

Zhou G, Kan X, Zhang F, Ji H, Sun J, Yang X

Cancers11 Dec 2022Cited by 7 (Europe PMC)

PMID36551579PMCIDPMC9777024DOI10.3390/cancers14246093PepBankPUB-36551579

Summary

Objective: To investigate the feasibility of interventional oncolytic immunotherapy with LTX-315 for residual tumors after incomplete radiofrequency ablation (iRFA) of VX2 liver tumors in a rabbit model. Methods: For in vitro experiments, VX2 tumor cells were treated with: (1) phosphate buffered saline, (2) radiofrequency hyperthermia (RFH), (3) LTX-315, and (4) RFH plus LTX-315. The residual tumors after iRFA of VX2 liver tumors were treated with: (1) phosphate buffered saline served as control, (2) 2 mg LTX-315, and (3) 4 mg LTX-315. MTS assay, fluorescence microscopy, and flow cytometry were used to compare cell viabilities and apoptosis among different groups. Ultrasound imaging was used to follow up the tumor growth, which were correlated with the optical imaging and subsequent histology. Results: For in vitro experiments, compared with the other three groups, MTS assay demonstrated the lowest cell viability, fluorescence microscopy showed the least survival cells, and apoptosis analysis revealed the highest percentage of apoptosis cells in the combination treatment groups (p < 0.001). For in vivo experiments, ultrasound imaging showed the smallest tumor volume in the group with 4 mg LTX-315 therapy compared with the other two groups (p < 0.001). The optical imaging and histopathological analysis showed complete necrosis of the tumors in the group with 4 mg LTX-315 therapy. A significant increase of CD8+ T cells and HSP70 and a significant decrease of Tregs were observed in residual tumors in the group with 2 mg LTX-315 therapy compared with the control group (p < 0.001). Conclusion: Interventional oncolytic immunotherapy with LTX-315 for residual tumors after iRFA of liver cancer is feasible, which may open up new avenues to prevent residual tumors after RFA of intermediate-to-large liver cancers.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study8

5 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In rabbits, 4 mg LTX‑315 produced the smallest residual tumor volumes compared with the other two groups.
In plain wordsIn rabbits, 4 mg LTX‑315 produced smaller tumors than saline and 2 mg LTX‑315.
Peptide
LTX-315
Outcome
DecreaseTumor volume
Study
rabbitn: not reported in source
Residual VX2 liver tumors after iRFA
Comparator
Phosphate buffered saline and 2 mg LTX-315
Outcome group
Tumor growth · Cancer
Studied dose
4 mgAs given in this study (rabbit).
Source sentences
Summary
For in vivo experiments, ultrasound imaging showed the smallest tumor volume in the group with 4 mg LTX-315 therapy compared with the other two groups (p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate the feasibility of interventional oncolytic immunotherapy with LTX-315 for residual tumors after incomplete radiofrequency ablation (iRFA) of VX2 liver tumors in a rabbit model.
Summary · context
The residual tumors after iRFA of VX2 liver tumors were treated with: (1) phosphate buffered saline served as control, (2) 2 mg LTX-315, and (3) 4 mg LTX-315.
Show in the study text Report a problemFND-3655157904
02AnimalAnimal study (in vivo)Efficacy outcome
In rabbits, 4 mg LTX‑315 produced complete tumor necrosis after incomplete ablation.
In plain wordsIn rabbits, 4 mg LTX‑315 produced complete tumor tissue death after incomplete ablation.
Peptide
LTX-315
Outcome
Direction not reportedTumor necrosis
Study
rabbitn: not reported in source
Residual VX2 liver tumors after iRFA
Outcome group
Tumor growth · Cancer
Studied dose
4 mgAs given in this study (rabbit).
Source sentences
Summary
The optical imaging and histopathological analysis showed complete necrosis of the tumors in the group with 4 mg LTX-315 therapy.
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the feasibility of interventional oncolytic immunotherapy with LTX-315 for residual tumors after incomplete radiofrequency ablation (iRFA) of VX2 liver tumors in a rabbit model.
Show in the study text Report a problemFND-3655157905
03AnimalAnimal study (in vivo)Mechanism
In rabbits, 2 mg LTX‑315 increased residual tumor CD8+ T cells compared with control.
In plain wordsIn rabbits, 2 mg LTX‑315 increased tumor CD8+ T cells compared with control.
Peptide
LTX-315
Outcome
IncreaseTumor CD8+ T cells
Study
rabbitn: not reported in source
Residual VX2 liver tumors after iRFA
Comparator
Control
Outcome group
Immune response · Cancer
Studied dose
2 mgAs given in this study (rabbit).
Source sentences
Summary
A significant increase of CD8+ T cells and HSP70 and a significant decrease of Tregs were observed in residual tumors in the group with 2 mg LTX-315 therapy compared with the control group (p < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the feasibility of interventional oncolytic immunotherapy with LTX-315 for residual tumors after incomplete radiofrequency ablation (iRFA) of VX2 liver tumors in a rabbit model.
Show in the study text Report a problemFND-3655157906
04AnimalAnimal study (in vivo)Mechanism
In rabbits, 2 mg LTX‑315 increased residual tumor HSP70 compared with control.
In plain wordsIn rabbits, 2 mg LTX‑315 increased tumor HSP70 compared with control.
Peptide
LTX-315
Outcome
IncreaseTumor HSP70
Study
rabbitn: not reported in source
Residual VX2 liver tumors after iRFA
Comparator
Control
Outcome group
Immune response · Cancer
Studied dose
2 mgAs given in this study (rabbit).
Source sentences
Summary
A significant increase of CD8+ T cells and HSP70 and a significant decrease of Tregs were observed in residual tumors in the group with 2 mg LTX-315 therapy compared with the control group (p < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the feasibility of interventional oncolytic immunotherapy with LTX-315 for residual tumors after incomplete radiofrequency ablation (iRFA) of VX2 liver tumors in a rabbit model.
Show in the study text Report a problemFND-3655157907
05AnimalAnimal study (in vivo)Mechanism
In rabbits, 2 mg LTX‑315 decreased residual tumor Tregs compared with control.
In plain wordsIn rabbits, 2 mg LTX‑315 reduced tumor regulatory T cells compared with control.
Peptide
LTX-315
Outcome
DecreaseTumor Tregs
Study
rabbitn: not reported in source
Residual VX2 liver tumors after iRFA
Comparator
Control
Outcome group
Immune response · Cancer
Studied dose
2 mgAs given in this study (rabbit).
Source sentences
Summary
A significant increase of CD8+ T cells and HSP70 and a significant decrease of Tregs were observed in residual tumors in the group with 2 mg LTX-315 therapy compared with the control group (p < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
To investigate the feasibility of interventional oncolytic immunotherapy with LTX-315 for residual tumors after incomplete radiofrequency ablation (iRFA) of VX2 liver tumors in a rabbit model.
Show in the study text Report a problemFND-3655157908

Studies that did not test the peptide alone3

In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking LTX-315.

06LabNot a test of LTX-315 aloneIn vitro (cells)Efficacy outcome
In VX2 cells, RFH plus LTX‑315 produced the lowest viability compared with the other three groups.
In plain wordsIn cells, RFH plus LTX‑315 produced lower viability than the other three groups.
Peptide
LTX-315
Outcome
DecreaseCell viability
Study
n: not reported in source
VX2 tumor cells
Comparator
Other three groups
Outcome group
Tumor growth · Cancer
Source sentences
Summary
For in vitro experiments, compared with the other three groups, MTS assay demonstrated the lowest cell viability, fluorescence microscopy showed the least survival cells, and apoptosis analysis revealed the highest percentage of apoptosis cells in the combination treatment groups (p < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
For in vitro experiments, VX2 tumor cells were treated with: (1) phosphate buffered saline, (2) radiofrequency hyperthermia (RFH), (3) LTX-315, and (4) RFH plus LTX-315.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Show in the study text Report a problemFND-3655157901
07LabNot a test of LTX-315 aloneIn vitro (cells)Efficacy outcome
In VX2 cells, RFH plus LTX‑315 produced the fewest surviving cells compared with the other three groups.
In plain wordsIn cells, RFH plus LTX‑315 produced fewer surviving cells than the other three groups.
Peptide
LTX-315
Outcome
DecreaseSurviving cells
Study
n: not reported in source
VX2 tumor cells
Comparator
Other three groups
Outcome group
Tumor growth · Cancer
Source sentences
Summary
For in vitro experiments, compared with the other three groups, MTS assay demonstrated the lowest cell viability, fluorescence microscopy showed the least survival cells, and apoptosis analysis revealed the highest percentage of apoptosis cells in the combination treatment groups (p < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
For in vitro experiments, VX2 tumor cells were treated with: (1) phosphate buffered saline, (2) radiofrequency hyperthermia (RFH), (3) LTX-315, and (4) RFH plus LTX-315.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Show in the study text Report a problemFND-3655157902
08LabNot a test of LTX-315 aloneIn vitro (cells)Efficacy outcome
In VX2 cells, RFH plus LTX‑315 produced the highest apoptosis percentage compared with the other three groups.
In plain wordsIn cells, RFH plus LTX‑315 produced more apoptosis than the other three groups.
Peptide
LTX-315
Outcome
IncreaseApoptotic cells
Study
n: not reported in source
VX2 tumor cells
Comparator
Other three groups
Outcome group
Tumor growth · Cancer
Source sentences
Summary
For in vitro experiments, compared with the other three groups, MTS assay demonstrated the lowest cell viability, fluorescence microscopy showed the least survival cells, and apoptosis analysis revealed the highest percentage of apoptosis cells in the combination treatment groups (p < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
For in vitro experiments, VX2 tumor cells were treated with: (1) phosphate buffered saline, (2) radiofrequency hyperthermia (RFH), (3) LTX-315, and (4) RFH plus LTX-315.
In this study, LTX-315 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking LTX-315.
Show in the study text Report a problemFND-3655157903

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
27 Oct 2026, 18:20 UTC
Study results updated
Version 1
27 Oct 2026, 16:32 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.